€1.11
Your prediction
Enlivex Therapeutics Ltd. Stock
Pros and Cons of Enlivex Therapeutics Ltd. in the next few years
Pros
Cons
Performance of Enlivex Therapeutics Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enlivex Therapeutics Ltd. | - | 0.000% | -11.200% | -50.000% | -50.446% | -87.528% | -95.184% |
| Oramed Pharmaceuticals | 2.110% | 3.075% | -7.215% | -24.685% | 4.537% | -83.591% | -25.080% |
| Galmed Pharmaceuticals Ltd. | -1.970% | 3.846% | -6.897% | -64.935% | -38.073% | -89.024% | - |
| Ardelyx Inc. | 5.770% | 6.941% | 7.836% | 67.751% | -1.903% | 364.754% | 79.034% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Enlivex Therapeutics reveals a complex portrait of a biotechnology company navigating through challenges amid the often turbulent landscape of medical research. The overall impression is that while potential exists, particularly considering its focus on innovative treatments, the company faces significant hurdles—in terms of profitability, revenue generation, and operational efficiency—that need to be addressed for it to realize its long-term goals.
Strong Asset Base: As of December 2023, Enlivex Therapeutics' balance sheet shows total assets of approximately $36.83 million, with a significant portion constituted by current assets ($33.76 million). This indicates a solid foundation, allowing the company to cover its short-term liabilities easily. The strong net working capital of roughly $27.70 million adds another layer of security, suggesting that Enlivex can manage its operational cash flows without straining its financial resources.
Market Capitalization: The market capitalization of roughly $104.82 million demonstrates a reasonably valued company within the biotechnology sector, which can be favorable in attracting potential investors. A market cap in this region indicates investors are willing to engage with the company, showing confidence in its market positioning despite its current financial struggles.